# A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

> **NCT07029945** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Biojiva LLC** · enrollment: 152 (estimated)

## Conditions studied

- Geographic Atrophy

## Interventions

- **DRUG:** BRX011
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07029945
- **Lead sponsor:** Biojiva LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-07
- **Primary completion:** 2026-11-11
- **Final completion:** 2027-02-11
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07029945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07029945, "A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07029945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*